Genomic Assay Predicts Biochemical Failure and Risk of Metastasis in Prostate Cancer Patients After Surgery and Radiation Therapy
|
By LabMedica International staff writers Posted on 13 Aug 2014 |
|
An advanced genomic test has been used to predict the course of prostate cancer in patients following surgery and radiation treatment.
Investigators at Thomas Jefferson University (Philadelphia, PA, USA) used the commercially available GenomeDx Biosciences (San Diego, CA, USA) Decipher assay system to analyze the genomes from tumor samples from 139 patients who had received radiation therapy following prostate surgery.
Decipher is a genomic test carried out on a small tissue sample that was removed during surgery, which measures the expression levels of 22 RNA biomarkers involved in multiple biological pathways across the genome associated with aggressive prostate cancer. The Decipher test uses the expression of these biomarkers to calculate the probability of clinical metastasis within five years of radical prostatectomy surgery and within three years of successive PSA rise (biochemical recurrence).
Results revealed that Decipher correctly predicted biochemical failure and risk of metastasis after prostate cancer postsurgical irradiation. It was suggested that patients with lower risk as defined by Decipher would benefit from delayed radiation treatment, as opposed to those with higher Decipher scores. However, this needs prospective validation in order to become generally accepted. Nonetheless, genomic-based models may be useful for improved decision-making for treatment of high-risk prostate cancer.
"We are moving away from treating everyone the same," said first author Dr. Robert Den, assistant professor of radiation oncology and cancer biology at Thomas Jefferson University. "Genomic tools are letting us gauge which cancers are more aggressive and should be treated earlier with radiation, and which ones are unlikely to benefit from additional therapy. Our analysis suggests that genomic analysis scores could be used, in concert with other diagnostic measures such as PSA testing, to help determine which patients would benefit from additional radiation therapy and more aggressive measures, and which are less likely to benefit."
The study was published in the July 8, 2014, online edition of the International Journal of Radiation Oncology*Biology*Physics.
Related Links:
Thomas Jefferson University
GenomeDx Biosciences
Investigators at Thomas Jefferson University (Philadelphia, PA, USA) used the commercially available GenomeDx Biosciences (San Diego, CA, USA) Decipher assay system to analyze the genomes from tumor samples from 139 patients who had received radiation therapy following prostate surgery.
Decipher is a genomic test carried out on a small tissue sample that was removed during surgery, which measures the expression levels of 22 RNA biomarkers involved in multiple biological pathways across the genome associated with aggressive prostate cancer. The Decipher test uses the expression of these biomarkers to calculate the probability of clinical metastasis within five years of radical prostatectomy surgery and within three years of successive PSA rise (biochemical recurrence).
Results revealed that Decipher correctly predicted biochemical failure and risk of metastasis after prostate cancer postsurgical irradiation. It was suggested that patients with lower risk as defined by Decipher would benefit from delayed radiation treatment, as opposed to those with higher Decipher scores. However, this needs prospective validation in order to become generally accepted. Nonetheless, genomic-based models may be useful for improved decision-making for treatment of high-risk prostate cancer.
"We are moving away from treating everyone the same," said first author Dr. Robert Den, assistant professor of radiation oncology and cancer biology at Thomas Jefferson University. "Genomic tools are letting us gauge which cancers are more aggressive and should be treated earlier with radiation, and which ones are unlikely to benefit from additional therapy. Our analysis suggests that genomic analysis scores could be used, in concert with other diagnostic measures such as PSA testing, to help determine which patients would benefit from additional radiation therapy and more aggressive measures, and which are less likely to benefit."
The study was published in the July 8, 2014, online edition of the International Journal of Radiation Oncology*Biology*Physics.
Related Links:
Thomas Jefferson University
GenomeDx Biosciences
Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
New
PSA Test
Humasis PSA Card
New
TRAb Immunoassay
Chorus TRAb
Latest Pathology News
- Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation
- World’s First AI Model for Thyroid Cancer Diagnosis Achieves Over 90% Accuracy
- Breakthrough Diagnostic Approach to Significantly Improve TB Detection
- Rapid, Ultra-Sensitive, PCR-Free Detection Method Makes Genetic Analysis More Accessible
- Spit Test More Accurate at Identifying Future Prostate Cancer Risk
- DNA Nanotechnology Boosts Sensitivity of Test Strips
- Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures
- New Error-Corrected Method to Help Detect Cancer from Blood Samples Alone
- "Metal Detector" Algorithm Hunts Down Vulnerable Tumors
- Novel Technique Uses ‘Sugar’ Signatures to Identify and Classify Pancreatic Cancer Cell Subtypes
- Advanced Imaging Reveals Mechanisms Causing Autoimmune Disease
- AI Model Effectively Predicts Patient Outcomes in Common Lung Cancer Type
- AI Model Predicts Patient Response to Bladder Cancer Treatment
- New Laser-Based Method to Accelerate Cancer Diagnosis
- New AI Model Predicts Gene Variants’ Effects on Specific Diseases
- Powerful AI Tool Diagnoses Coeliac Disease from Biopsy Images with Over 97% Accuracy
Channels
Clinical Chemistry
view channel
‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read more
Molecular Diagnostics
view channel
New Genetic Tool Analyzes Umbilical Cord Blood to Predict Future Disease
Children are experiencing metabolic problems at increasingly younger ages, placing them at higher risk for serious health issues later in life. There is a growing need to identify this risk from birth... Read more
Spinal Fluid Biomarker for Parkinson’s Disease Offers Early and Accurate Diagnosis
Parkinson’s disease is a neurodegenerative condition typically diagnosed at an advanced stage based on clinical symptoms, primarily motor disorders. However, by this time, the brain has already undergone... Read more
Hematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read more
Immunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read more
Microbiology
view channel
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Technology
view channel
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read more
Industry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more
